- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Elagolix with add-back therapy promising for endometriosis-associated pain: Ongoing phase 3 trial reveals
USA: In a significant advancement in the treatment of endometriosis, preliminary findings from an ongoing randomized Phase 3 trial have unveiled promising outcomes with elagolix combined with add-back therapy.
The study, published in the American Journal of Obstetrics and Gynecology, showed that compared with placebo, elagolix with add-back therapy led to significant, clinically meaningful improvement in nonmenstrual pelvic pain, dysmenorrhea, and fatigue at six months that continued until month 12 for both nonmenstrual pelvic pain and dysmenorrhea.
In addition, elagolix combined with add-back therapy demonstrated good tolerability overall. Over 12 months, patients receiving this combination showed a slightly higher reduction in bone mineral density (BMD) compared to those on placebo. However, the decrease in BMD with elagolix plus add-back therapy was less than 1%, significantly lower than the bone loss seen in patients receiving elagolix alone.
Elagolix, an FDA-approved oral treatment for managing endometriosis-associated pain, is known to induce hypoestrogenic effects when used alone. Incorporating hormonal add-back therapy has shown promise in counteracting these effects. Considering this, Charles E. Miller, the Advanced Gynecologic Surgery Institute, Park Ridge, IL, and colleagues aimed to evaluate tolerability, efficacy, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol /0.5 mg norethindrone acetate (add-back) therapy once daily than placebo in premenopausal women with moderate-to-severe endometriosis-associated pain.
The ongoing, 48-month, phase 3 study comprised a 12-month, double-blind period, with randomization 4:1:2 to elagolix 200 mg twice daily with add-back therapy, elagolix 200 mg twice daily monotherapy for six months followed by elagolix with add-back therapy, or placebo.
The study's co-primary objectives were to determine the proportion of patients showing clinical improvement, termed "responders," in dysmenorrhea and nonmenstrual pelvic pain by month 6. The study presents the 12-month findings on the effectiveness of elagolix combined with add-back therapy compared to placebo in reducing symptoms of nonmenstrual pelvic pain, dysmenorrhea, dyspareunia, and fatigue. Tolerability assessments included monitoring adverse events and evaluating changes in bone mineral density from baseline.
The study led to the following findings:
- A total of 679 patients were randomized to elagolix with add-back therapy (n=389), elagolix monotherapy (n=97), or placebo (n=193).
- Compared with patients randomized to placebo, a significantly greater proportion of patients randomized to elagolix with add-back therapy responded with clinical improvement in dysmenorrhea (62.8% versus 23.7%) and nonmenstrual pelvic pain (51.3% versus 36.8%) at six months.
- Compared with placebo, elagolix with add-back therapy produced significantly greater improvement from baseline in 7 hierarchically ranked secondary endpoints, including dysmenorrhea (months 12, 6, 3), nonmenstrual pelvic pain (months 12, 6, 3), and fatigue (months 6).
- The incidence of adverse events was 73.8% with elagolix plus add-back therapy and 66.8% with placebo.
- The rate of severe adverse events did not meaningfully differ between treatment groups.
- Study drug discontinuations associated with adverse events were low in patients receiving elagolix with add-back therapy (12.6%) and those receiving placebo (9.8%).
- Patients randomized to elagolix monotherapy exhibited decreases from baseline in bone mineral density of −2.43% (lumbar spine), −1.54% (total hip), and −1.78% (femoral neck) at month 6.
- When add-back therapy was added to elagolix at month 6, the change from baseline in bone mineral density remained in a similar range of −1.58% to −1.83% at month 12.
- Patients who received elagolix plus add-back therapy from baseline exhibited little change from baseline in BMD (<1% change) at months 6 and 12.
The initial findings offer hope for improved treatment options and enhanced quality of life for women with chronic pain and complications of endometriosis.
Reference:
Miller, C. E., Kim, J. H., Kroll, R., Simon, J. A., Soliman, A. M., Thomas, J. W., Xu, Y., Ng, J., & Snabes, M. C. (2024). Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: 12 months of an ongoing randomized phase 3 trial. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2024.06.040
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751